Your gut bacteria play a surprisingly powerful role in whether cancer immunotherapy works, and disruptions in this microscopic ecosystem may be silently undermining treatment success for thousands of patients. Scientists are discovering that the composition of bacteria in your digestive system directly influences how well your immune system responds to cutting-edge cancer therapies like checkpoint inhibitors and CAR-T (chimeric antigen receptor T-cell) therapy. This emerging understanding is reshaping how oncologists think about optimizing cancer care beyond just the drugs themselves.

How Does the Gut Microbiome Affect Cancer Immunotherapy?

The gut microbiome is a complex ecosystem of trillions of bacteria that do far more than aid digestion. These microorganisms produce metabolites, chemical compounds that influence how your body metabolizes drugs and how your immune cells function. Certain bacterial species can enhance immune responses to cancer treatments, while others actively suppress them. Researchers have found that specific bacteria are associated with better treatment outcomes, whereas others can reduce survival rates.

When this bacterial balance is disrupted, a condition called dysbiosis, the consequences for cancer patients are significant. About 50% to 60% of patients with cancer experience dysbiosis, compared to only about 20% of healthy individuals. This imbalance is now recognized as a key biomarker for predicting whether immunotherapy will work. Dysbiosis reduces the diversity of beneficial bacteria and allows harmful bacteria to proliferate, which impairs critical immune functions needed for treatment success.

"We learned that dysbiosis is a key biomarker of response and resistance to immunotherapy. As a result, multiple microbiota interventions and clinical trials are being developed with the goal of transforming an unfavorable microbiome associated with resistance to immunotherapy to that of a favorable microbiome associated with a robust immune response," explained Arielle Elkrief, MD, from the University of Montreal.

Arielle Elkrief, MD, University of Montreal

Why Do Antibiotics Undermine Cancer Treatment?

One of the most striking findings is that antibiotic use, while necessary for fighting infections, can significantly harm cancer treatment outcomes. Antibiotics eliminate both harmful and beneficial bacteria indiscriminately, disrupting the microbiome's delicate balance. Studies show that cancer patients who receive antibiotics have lower overall survival rates and reduced responses to immunotherapy, including checkpoint inhibitors, CAR-T therapy, and stem cell transplantation. The risk of death increases by 70% (a hazard ratio of 1.7) in patients exposed to antibiotics during cancer treatment.

The mechanism behind this harm is multifaceted. Antibiotics impair immunosurveillance, the immune system's natural ability to detect and eliminate early cancer cells before they develop into tumors. They also increase T-cell exhaustion, a condition where immune cells become worn out and unable to fight cancer effectively. These effects underscore why careful antibiotic stewardship is critical for cancer patients.

How Can Doctors Optimize the Microbiome During Cancer Treatment?

Recognizing the microbiome's importance, oncologists and researchers are developing targeted strategies to restore healthy bacterial balance and improve treatment outcomes. The approach depends on the severity of dysbiosis and ranges from simple dietary changes to more intensive interventions.

• Mild Dysbiosis: Discontinuing unnecessary medications and increasing dietary fiber intake to feed beneficial bacteria and restore diversity naturally.
• Moderate Dysbiosis: Using prebiotics (compounds that feed good bacteria), live bacterial products, and addressing sites of inflammation in the gut to restore balance.
• Severe Dysbiosis: Fecal microbiota transplantation (FMT), a procedure where healthy donor stool is transplanted into the patient's digestive system to replace the dysbiotic microbiome with beneficial bacteria.

FMT has shown particularly promising results in clinical trials. In the phase 2 TACITO trial, 66.7% of patients with renal cell carcinoma achieved progression-free survival one year after receiving FMT. The FMT-LUMINATE study, which assessed FMT in patients with lung cancer, met its primary endpoint with an 80% overall response rate to immunotherapy. FMT is administered as an odorless, tasteless oral capsule containing approximately 200 grams of healthy donor stool, making it a practical option for patients.

"We might envision treating mild dysbiosis by discontinuing inappropriate medications and addressing nutritional imbalances. For moderate dysbiosis, targeting sites of inflammation may be beneficial, along with the use of prebiotics and potentially live biotherapeutics. In cases of severe dysbiosis, even interventions such as fecal microbiota transplantation may prove valuable," stated Laurence Zitvogel, MD, PhD, from the Institut Gustave Roussy Strategies in Montreal.

Laurence Zitvogel, MD, PhD, Institut Gustave Roussy Strategies in Montreal

What Practical Steps Should Cancer Patients Take?

For patients undergoing immunotherapy, protecting the gut microbiome should be a priority conversation with their oncology team. Doctors are increasingly recommending a judicious approach to antibiotic prescribing, using the narrowest spectrum antibiotic for the shortest effective duration whenever infection treatment is necessary. Monitoring microbiome changes during antibiotic treatment can help inform future therapeutic decisions and support better outcomes.

Beyond antibiotics, dietary interventions show promise in supporting a healthy microbiome during cancer treatment. While the sources indicate that dietary approaches are part of the microbiome optimization strategy, the specific foods and nutrients are being studied in ongoing clinical trials. Patients should work with their oncology team and, ideally, a nutritionist familiar with cancer immunotherapy to develop a personalized approach.

The emerging science of the cancer microbiome represents a significant shift in how doctors approach treatment optimization. Rather than viewing cancer therapy as solely about the medication, oncologists are now recognizing that the patient's internal ecosystem plays a critical role in determining success. As more clinical trials validate microbiome-focused interventions, personalized cancer care may increasingly include strategies to assess and restore gut health alongside conventional immunotherapy.